Citations 31
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
Jurinović, Vindi , Kridel, Robert , Szczepanowski, Monika , Horn, Heike , Dreyling, Martin , Rosenwald, Andreas , Ott, German , Klapper, Wolfram , Friedberg, Jonathan W. , Ansell, Stephen M. , Gascoyne, Randy D. , Unterhalt, Michael, Weinstock, David M. , Weigert, Oliver , Kridel, Robert , Staiger, Annette M. , Klapper, Wolfram , Zelenetz, Andrew D. , Barr, Paul M. , Sehn, Laurie H. , Connors, Joseph M.
Blood | July 14, 2016 | Volume: 128 | Issue: 8 | Pages: 1112-1120
Key Points The posttreatment end point progression of FL within 24 months (POD24) is strongly associated with OS. A pretreatment clinicogenetic risk model (m7-FLIPI) predicts POD24 and OS and identifies the smallest subgroup with highest unmet need.